Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
The development of vaccines against SARS-CoV-2 would be greatly facilitated by the identification of immunological correlates of protection in humans. However, to date, studies on protective immunity have been performed only in animal models and correlates of protection have not been established in humans. Here, we describe an outbreak of SARS-CoV-2 on a fishing vessel associated with a high attack rate. Predeparture serological and viral reverse transcription-PCR (RT-PCR) testing along with repeat testing after return to shore was available for 120 of the 122 persons on board over a median follow-up of 32.
Article activity feed
-
SciScore for 10.1101/2020.08.13.20173161: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: This study was approved by the University of Washington Institutional Review Board. Randomization The strains were then stratified by Pangolin lineage (A or B) (https://github.com/cov-lineages/pangolin) and 49 from lineage A and 59 from lineage B were randomly selected along with the Wuhan-Hu-1 reference genome (NC_045512.2) (25). Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Neutralization Assays and Anti-Spike Antibody Testing: The presence of anti-Spike and neutralizing antibodies was analyzed in pre-departure sera samples from individuals that were positive in the … SciScore for 10.1101/2020.08.13.20173161: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: This study was approved by the University of Washington Institutional Review Board. Randomization The strains were then stratified by Pangolin lineage (A or B) (https://github.com/cov-lineages/pangolin) and 49 from lineage A and 59 from lineage B were randomly selected along with the Wuhan-Hu-1 reference genome (NC_045512.2) (25). Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Neutralization Assays and Anti-Spike Antibody Testing: The presence of anti-Spike and neutralizing antibodies was analyzed in pre-departure sera samples from individuals that were positive in the Abbott assay screening through four different methods: Spike IgG ELISA, RBD ELISA, ACE2 blockade of binding ELISA, and pseudovirus neutralization. Anti-Spikesuggested: NonePooled sera collected from 2017-2018 from 75 individuals (Gemini Biosciences, 100-110, lot H86W03J) and CR3022 antibody (starting at 1/ug/mL, also diluted 4-fold) were included as negative and positive controls, respectively. CR3022suggested: (Imported from the IEDB Cat# CR3022, RRID:AB_2848080)Plates were again washed three times, and then 50μL of a 1:300 dilution of goat anti-human IgG-Fc horseradish peroxidase (HRP)-conjugated antibody (Bethyl Labs, A80-104P) in PBS-T containing 1% milk was added to each well and incubated for 1 hour at room temperature. anti-human IgG-Fcsuggested: (Bethyl Cat# A80-104P, RRID:AB_67064)Software and Algorithms Sentences Resources Clinical testing of serum samples was performed using the Abbott Architect SARS-CoV-2 IgG assay (20). Abbott Architectsuggested: (Abbott ARCHITECT i1000sr System, RRID:SCR_019328)Sequencing reads are available at NCBI BioProject PRJNA610428 and sequence accessions are available in Supplemental Table 1. BioProjectsuggested: (NCBI BioProject, RRID:SCR_004801)Briefly, sequencing reads were adapter- and quality-trimmed with BBDuk and mapped to the SARS-CoV-2 reference genome (NC_045512.2) using Bowtie 2 (23). Bowtiesuggested: (Bowtie, RRID:SCR_005476)Reads aligning to the SARS-CoV-2 reference genome were filtered using BBDuk and assembled with SPAdes (24). SPAdessuggested: (SPAdes, RRID:SCR_000131)For samples that did not produce a genome through the automated pipeline, the mapped read assemblies were visualized in Geneious and a consensus genome was called manually. Geneioussuggested: (Geneious, RRID:SCR_010519)Sequences were aligned with MAFFT v7.453 (26) and a phylogenetic tree was constructed using FastTree (version 2.1.1) (27) with the 5’ and 3’UTRs masked. MAFFTsuggested: (MAFFT, RRID:SCR_011811)FastTreesuggested: (FastTree, RRID:SCR_015501)Strains most closely related to the major outbreak clade were identified by searching against a custom BLASTN database containing all SARS-CoV-2 sequences in GISAID (accessed August 3, 2020). BLASTNsuggested: (BLASTN, RRID:SCR_001598)Neutralization Assays and Anti-Spike Antibody Testing: The presence of anti-Spike and neutralizing antibodies was analyzed in pre-departure sera samples from individuals that were positive in the Abbott assay screening through four different methods: Spike IgG ELISA, RBD ELISA, ACE2 blockade of binding ELISA, and pseudovirus neutralization. Abbottsuggested: (Abbott, RRID:SCR_010477)After calculating the fraction infectivity, we used the neutcurve Python package (https://jbloomlab.github.io/neutcurve/) to calculate the serum dilution that inhibited infection by 50% (IC50) by fitting a Hill curve with the bottom fixed at 0 and the top fixed at 1. Pythonsuggested: (IPython, RRID:SCR_001658)Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
-